BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Allegro Diagnostics Closes on $5.4M Financing


7/7/2011 10:20:30 AM

MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced that it has closed a $5.4M Series A extension financing. The company’s existing venture investors, Kodiak Venture Partners and Catalyst Health Ventures, participated in the round. The company has developed a molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Proceeds from the financing will support the commercialization of Allegro’s lead genomic test, BronchoGen™, in 2012.

“This support from our existing investors reflects their enthusiasm for Allegro’s focus on early lung cancer detection,” said Michael D. Webb, President and CEO of Allegro Diagnostics. "Approximately 300,000 bronchoscopic exams are performed each year, but the majority of the results are inconclusive. As a consequence, most individuals with suspected lung cancer do not receive a definitive diagnosis, and therefore may not receive treatment until it is too late. The BronchoGen genomic test has been developed to fill this gap. When used alongside standard bronchoscopy procedures, BronchoGen is intended to provide additional critical diagnostic information much earlier in the diagnostic process.”

“Allegro is leading a new paradigm for lung cancer management by introducing the potential for early detection, and we believe that this approach has great promise both clinically and commercially,” said Andrey Zarur, Managing Partner at Kodiak Venture Partners. “Lung cancer is the leading cancer killer, and, unfortunately, 70% of patients are not diagnosed until they have progressed to late-stage disease. BronchoGen is designed to support earlier diagnosis, which may potentially reduce mortality and healthcare costs.”

About the Allegro Platform

Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The “field of injury” principle on which the platform is based refers to the common molecular response that occurs throughout the respiratory tract in current and former smokers with lung cancer. These changes can be detected in a gene expression signature from non-malignant airway cells and indicate the presence of malignancy remotely in the lung. Allegro has applied this platform to generate multiple product candidates.

About Allegro Diagnostics

Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the early diagnosis of lung cancer. www.allegrodx.com

Contacts

MacDougall Biomedical Communications
Jennifer Conrad, 781-235-3060
jconrad@macbiocom.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->